Clicky

Ono Pharmaceutical(OPHLF)

Description: Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company's products include OPDIVO intravenous infusions for treating malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Glactiv and FORXIGA tablets for type II diabetes; Kinedak tablets to treat diabetic peripheral neuropathy; Recalbon tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease treatment; Onoact injections for treating tachyarrhythmia; Staybla tablets for overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; Onon capsules and dry syrups for treating bronchial asthma and allergic rhinitis; and Foipan tablets for treating chronic pancreatitis and postoperative reflux esophagitis. It is also developing products for gastric, colorectal, small and non-small cell lung, head and neck, urothelial, esophageal, ovarian, biliary tract, hematologic cancers; and hodgkin lymphoma, hepatocellular carcinoma, glioblastoma, malignant pleural mesothelioma, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, solid tumor, central nervous system lymphoma, primary testicular lymphoma, virus positive/negative solid carcinoma, chronic myeloid leukemia, cancer anorexia/cachexia, melanoma, pheochromocytoma, acute leukemia, juvenile idiopathic arthritis, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, tachyarrhythmia, ventricular arrhythmia, sepsis, hepatitis C, parkinson's disease, overactive bladder, osteoarthritis, sjögren syndrome, and underactive bladder. Ono Pharmaceutical Co., Ltd. has collaboration agreements with Eisai Co., Ltd. and Schrödinger Inc., Fate Therapeutics, Inc., and Merus N.V. The company was founded in 1717 and is headquartered in Osaka, Japan.


Keywords: Medicine Cancer Clinical Medicine Diabetes Oncology Alzheimer's Disease Parkinson's Disease Chemotherapy Rheumatoid Arthritis Lymphoma Asthma Hepatitis Arthritis Multiple Myeloma Melanoma Osteoarthritis Leukemia Osteoporosis Hematology Heart Failure Glioblastoma Carcinoma Hepatocellular Carcinoma Blastoma Hepatitis C Syrup Anatomical Pathology Sepsis Nausea Peripheral Neuropathy Hodgkin Lupus Rhinitis Arrhythmia Stoma Allergic Rhinitis Flux Overactive Bladder Small Cell Follicular Lymphoma Mesothelioma I Diabetes Chronic Myeloid Leukemia Chronic Heart Failure Diffuse Large B Cell Lymphoma Intravenous Infusion Acute Leukemia Lupus Nephritis Malignant Pleural Mesothelioma Myeloid Leukemia Chemotherapy Induced Nausea Ii Diabetes Tomy Bronchial Asthma Diabetic Peripheral Neuropathy Eisai Orencia Pancreatitis Cachexia Hematologic Cancers Sjögren Syndrome Juvenile Idiopathic Arthritis Malignant Tumor Opdivo Folli Intravenous Infusions Central Nervous System Lymphoma Chronic Pancreatitis Opalmon Peripheral Circulatory Disorder Pheochromocytoma Polymyositis/Dermatomyositis Positive/Negative Solid Carcinoma Proteasome Recalbon Staybla Tachyarrhythmia

Home Page: www.ono-pharma.com

8-2, Kyutaromachi 1-chome
Osaka, 541-8564
Japan
Phone: 81 6 6263 5670


Officers

Name Title
Mr. Gyo Sagara CEO & Chairman of the Board
Mr. Toichi Takino Ph.D. President, COO & Representative Director
Mr. Masaki Ito Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., and Corp. Tax
Takehiro Yamada Corporate Officer & Head of Risk and Compliance Management Department
Satoshi Takahagi Corporate Executive Off. and Exe. Dir. of Sales, Marketing & Oncology Business Division
Masayuki Tanigawa Corporate Officer & Head of Business Strategy Headquarters
Mr. Toshihiro Tsujinaka Ex. EO, Exe. Dir. of Sus. Promotion Corp. Strategy, Planning & HR Divi. and Representative Dir.
Hiromu Habashita Ph.D. Corporate Officer & Deputy Executive Director, Discovery & Research
Shinji Takai M.D., Ph.D. Corporate Officer & Head of Medical Affairs
Akira Takada Corporate Executive Officer, Executive Director, CMC & Production, Production Technology Management

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 13.8696
Trailing PE: 9.3985
Price-to-Book MRQ: 1.0082
Price-to-Sales TTM: 0.011
IPO Date:
Fiscal Year End: March
Full Time Employees: 4258
Back to stocks